middle.news
Paradigm Reverses US$2 Million Drawdown as Trial Review Continues
3:25pm on Thursday 24th of September, 2026 AEST
•
Biotechnology and Pharmaceuticals
Read Story
Paradigm Reverses US$2 Million Drawdown as Trial Review Continues
3:25pm on Thursday 24th of September, 2026 AEST
Key Points
US$2 million Tranche 4 drawdown to be returned to Obsidian
2 million convertible notes cancelled with no premium or fee
Interim PARA_OA_012 Phase 3 analysis remains under review
Available cash and funds owed to Obsidian will both decrease
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE